GSK3359609: Phase I started

GlaxoSmithKline began the open-label, dose-escalation, dose-expansion, international Phase I INDUCE-1 trial to evaluate IV

Read the full 140 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE